Market Cap 6.73B
Revenue (ttm) 22.29M
Net Income (ttm) -228.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,027.05%
Debt to Equity Ratio 0.00
Volume 14,666,200
Avg Vol 2,810,162
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 77%
Beta 0.25
Analysts Sell
Price Target $112.85

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
Night_Owl_Biotech
Night_Owl_Biotech Jun. 16 at 1:47 AM
The 5 analysts that provide 10-year $MLYS revenue estimates all project MLYS to generate more product related revenues over the next 10 years than $ACLX , not 1 or 2 analysts but all 5. Of course we have no idea the gross margin profiles for either but if sales are a barometer of potential value then... ACLX was acquired for an enterprise value of $7.3B while MLYS's market cap was $2.1B as of 6/15/26, which does not consider the $650MM MLYS had on their balance sheet at the end of Q1 26 As important, MLYS just closed a meaningful equity raise 2 weeks where accredited investors opted to invest $150MM in MLYS at $26.50. MLYS closed at just under $24.00 today. This is not investment advice but if all 5 analysts believe MLYS' product portfolio will generate meaningfully more sales than ACLX, and ACLX's enterprise value is 4X higher then... $XBI $IBB $NBI
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 14 at 1:13 PM
$IDYA analyst consensus revenue estimates versus $NUVL & $ACLX via graph & simple 5-year revenue multiple comparison. ACLX was acquired for an EV of $7.3B & NUVB was $9.4B (rounded). None of the 3 have a FDA approved therapy yet though obviously NUVL & ACLX had active PDUFA dates when acquired. Our simple question...if analysts believe IDYA will meaningfully outsell ACLX and, more or less, generate revenues consistent with NUVL, does this suggest IDYA's risk v reward profile is compelling? Are there any reasons IDYA's valuation as a multiple of analysts estimates won't match the 2 (assuming BLA's are submitted)? This is not investment advice. $XBI $NBI
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 13 at 10:01 PM
This is not investment advice. We have no idea what $RVMD might be worth in a hypothetical acquisition. That being said, $NUVL & $ACLX were acquired for an average of 1.5X analyst 5-year FY28 - 32 revenue estimates, excluding the highest estimate for each year, as detailed on the attachment. The 7 RVMD analysts that provide RVMD FY28 - 32 revenue estimates project RVMD to generate $28.421B in revenues over the same 5-year period. Hence if RVMD analyst estimates were credible AND if RVMD were acquired at the same average 5-year revenue multiple of 1.5X (2 ENORMOUS IFs) then RVMD would exit for $42.63B in EV (consistent with NUVL & ACLX multiples). Using RVMD's 3/31/26 cap table, this would be ~$200 per share. We're curious if investors believe RVMD's profile would merit a peer M&A revenue multiple consistent with NUVL & ACLX? Why or why not (i.e. gross margin profile is different, royalty obligations)? We'd genuinely appreciate feedback. This is not investment advice. $XBI $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 9 at 2:06 PM
$NUVL M&A revenue multiples v. peer pre-commercial stage M&A (with active PDUFAs) plus 5 commercial-stage bios acquired very shortly post FDA approval. $ACLX is included as a peer Using NUVL's 3/31/2026 Cap Table, we get a fully diluted enterprise value of $9.383B or call it $9.4B (calculation attached that reconciles to the $10.6B market cap per NUVL press release). NUVL Year 1 - 10 = FY2027 - FY2036 analyst consensus per Seeking Alpha. The peer transactions take year 1 - 10 per the acquiree management. We will update this analysis when NUVL files their 14D9 with the SEC in about 4 weeks The attached analysis (that has not been verified) suggests NUVL is being acquired at one of the highest revenue multiples in this peer group (assuming analyst consensus is more or less accurate. Investors in $RVMD & $CELC may want to review. This is not investment advice $CLDX
1 · Reply
Bobear12
Bobear12 May. 23 at 9:38 PM
$ACLX Galectin Therapeutics (NASDAQ: GALT) is presenting new clinical analyses of its Phase 2b NAVIGATE trial for its lead drug, belapectin, at the EASL Congress. The presentations at the European Association for the Study of the Liver focus on preventing esophageal varices and improving liver biomarkers in patients with MASH cirrhosis.
0 · Reply
TeresaTrades
TeresaTrades Apr. 28 at 1:21 PM
Largest CALL OI decreases $PLTR $NOK $ACLX $LVS $IVZ
0 · Reply
TwongStocks
TwongStocks Apr. 24 at 6:21 PM
$ACLX Equity Corporate Actions Alert #2026 - 272 Information Regarding the Merger of Arcellx, Inc. (ACLX) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-272 The tender offer by Gilead Sciences, Inc. $GILD to acquire all of the outstanding common stock of Arcellx, Inc. $ACLX is scheduled to expire at 5:00 p.m. ET, on April 27, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on April 28, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 27, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 28th) and will be suspended effective April 29, 2026. The details are as follows:
0 · Reply
Mergerbrief
Mergerbrief Apr. 24 at 12:07 PM
$ACLX / $GILD – Tender Offer Expires Today
0 · Reply
TwongStocks
TwongStocks Apr. 17 at 12:32 PM
$GILD Gilead Receives All Required Regulatory Approvals for the Acquisition of $ACLX Arcellx and Extends Tender Offer https://www.businesswire.com/news/home/20260417916113/en/Gilead-Receives-All-Required-Regulatory-Approvals-for-the-Acquisition-of-Arcellx-and-Extends-Tender-Offer "The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions. "
0 · Reply
DonCorleone77
DonCorleone77 Apr. 1 at 8:16 PM
$ACLX $GILD Gilead extends tender offer to acquire Arcellx Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
0 · Reply
Latest News on ACLX
Arcellx Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Arcellx Annual report: Q4 2025


Here's Why Shares of Arcellx Are Up Almost 80% Today

Feb 23, 2026, 2:25 PM EST - 4 months ago

Here's Why Shares of Arcellx Are Up Almost 80% Today


Why is Arcellx stock up 80% today? Gilead's $7.8B answer

Feb 23, 2026, 8:41 AM EST - 4 months ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

GILD


Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Feb 23, 2026, 6:36 AM EST - 4 months ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

GILD


Gilead to acquire Arcellx for $7.8 billion

Feb 23, 2026, 6:08 AM EST - 4 months ago

Gilead to acquire Arcellx for $7.8 billion

GILD


Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 6 months ago

Cancer Study Buoys These Small Biotechs

LEGN TERN


Arcellx Transcript: Status Update

Dec 6, 2025, 8:00 PM EST - 7 months ago

Arcellx Transcript: Status Update


Arcellx Press release: Status Update

Dec 6, 2025, 8:00 PM EST - 7 months ago

Arcellx Press release: Status Update


Arcellx Slides: Status Update

Dec 6, 2025, 8:00 PM EST - 7 months ago

Arcellx Slides: Status Update


Arcellx Provides Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 8 months ago

Arcellx Provides Third Quarter 2025 Financial Results


Arcellx Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Arcellx Earnings release: Q3 2025


Arcellx Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Arcellx Quarterly report: Q3 2025


Arcellx Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Arcellx Earnings release: Q2 2025


Arcellx Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Arcellx Quarterly report: Q2 2025


Arcellx Transcript: Status Update

Jun 13, 2025, 2:30 PM EDT - 1 year ago

Arcellx Transcript: Status Update


Arcellx Slides: Corporate Presentation

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Arcellx Slides: Corporate Presentation


Arcellx Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Arcellx Earnings release: Q1 2025


Arcellx Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Arcellx Quarterly report: Q1 2025


Arcellx Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Arcellx Proxy statement: Proxy Filing


Arcellx Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Arcellx Proxy statement: Proxy Filing


Arcellx Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Arcellx Annual report: Q4 2024


Arcellx Transcript: Status Update

Dec 9, 2024, 11:00 PM EST - 1 year ago

Arcellx Transcript: Status Update


Arcellx Press release: Status Update

Dec 9, 2024, 11:00 PM EST - 1 year ago

Arcellx Press release: Status Update


Arcellx Slides: Status Update

Dec 9, 2024, 11:00 PM EST - 1 year ago

Arcellx Slides: Status Update


Arcellx Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Arcellx Earnings release: Q3 2024


Arcellx Quarterly report: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Arcellx Quarterly report: Q3 2024


Arcellx Quarterly report: Q2 2024

Aug 9, 2024, 4:00 PM EDT - 2 years ago

Arcellx Quarterly report: Q2 2024


Arcellx Earnings release: Q2 2024

Aug 9, 2024, 4:00 PM EDT - 2 years ago

Arcellx Earnings release: Q2 2024


Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter 2024 Financial Results


Arcellx Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Arcellx Quarterly report: Q1 2024


Arcellx Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Arcellx Earnings release: Q1 2024


Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate in Two Upcoming Investor Conferences


Arcellx Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Arcellx Proxy statement: Proxy Filing


Arcellx Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Arcellx Proxy statement: Proxy Filing


Arcellx Earnings release: Q4 2023

Feb 28, 2024, 7:00 AM EST - 2 years ago

Arcellx Earnings release: Q4 2023


Arcellx Annual report: Q4 2023

Feb 28, 2024, 7:00 AM EST - 2 years ago

Arcellx Annual report: Q4 2023


Kite and Arcellx Announce Expansion in Strategic Partnership

Nov 15, 2023, 6:00 AM EST - 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD


ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Nov 15, 2023, 6:00 AM EST - 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD


Arcellx Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Arcellx Quarterly report: Q3 2023


Arcellx Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Arcellx Earnings release: Q3 2023


Arcellx Quarterly report: Q1 2023

Aug 5, 2023, 7:00 AM EDT - 3 years ago

Arcellx Quarterly report: Q1 2023


Arcellx Earnings release: Q1 2023

Aug 5, 2023, 7:00 AM EDT - 3 years ago

Arcellx Earnings release: Q1 2023


Arcellx Provides First Quarter Financial Results

May 8, 2023, 4:00 PM EDT - 3 years ago

Arcellx Provides First Quarter Financial Results


Arcellx Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Arcellx Proxy statement: Proxy Filing


Arcellx Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Arcellx Proxy statement: Proxy Filing


Arcellx Proxy statement: Proxy Filing

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Arcellx Proxy statement: Proxy Filing


Night_Owl_Biotech
Night_Owl_Biotech Jun. 16 at 1:47 AM
The 5 analysts that provide 10-year $MLYS revenue estimates all project MLYS to generate more product related revenues over the next 10 years than $ACLX , not 1 or 2 analysts but all 5. Of course we have no idea the gross margin profiles for either but if sales are a barometer of potential value then... ACLX was acquired for an enterprise value of $7.3B while MLYS's market cap was $2.1B as of 6/15/26, which does not consider the $650MM MLYS had on their balance sheet at the end of Q1 26 As important, MLYS just closed a meaningful equity raise 2 weeks where accredited investors opted to invest $150MM in MLYS at $26.50. MLYS closed at just under $24.00 today. This is not investment advice but if all 5 analysts believe MLYS' product portfolio will generate meaningfully more sales than ACLX, and ACLX's enterprise value is 4X higher then... $XBI $IBB $NBI
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 14 at 1:13 PM
$IDYA analyst consensus revenue estimates versus $NUVL & $ACLX via graph & simple 5-year revenue multiple comparison. ACLX was acquired for an EV of $7.3B & NUVB was $9.4B (rounded). None of the 3 have a FDA approved therapy yet though obviously NUVL & ACLX had active PDUFA dates when acquired. Our simple question...if analysts believe IDYA will meaningfully outsell ACLX and, more or less, generate revenues consistent with NUVL, does this suggest IDYA's risk v reward profile is compelling? Are there any reasons IDYA's valuation as a multiple of analysts estimates won't match the 2 (assuming BLA's are submitted)? This is not investment advice. $XBI $NBI
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 13 at 10:01 PM
This is not investment advice. We have no idea what $RVMD might be worth in a hypothetical acquisition. That being said, $NUVL & $ACLX were acquired for an average of 1.5X analyst 5-year FY28 - 32 revenue estimates, excluding the highest estimate for each year, as detailed on the attachment. The 7 RVMD analysts that provide RVMD FY28 - 32 revenue estimates project RVMD to generate $28.421B in revenues over the same 5-year period. Hence if RVMD analyst estimates were credible AND if RVMD were acquired at the same average 5-year revenue multiple of 1.5X (2 ENORMOUS IFs) then RVMD would exit for $42.63B in EV (consistent with NUVL & ACLX multiples). Using RVMD's 3/31/26 cap table, this would be ~$200 per share. We're curious if investors believe RVMD's profile would merit a peer M&A revenue multiple consistent with NUVL & ACLX? Why or why not (i.e. gross margin profile is different, royalty obligations)? We'd genuinely appreciate feedback. This is not investment advice. $XBI $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 9 at 2:06 PM
$NUVL M&A revenue multiples v. peer pre-commercial stage M&A (with active PDUFAs) plus 5 commercial-stage bios acquired very shortly post FDA approval. $ACLX is included as a peer Using NUVL's 3/31/2026 Cap Table, we get a fully diluted enterprise value of $9.383B or call it $9.4B (calculation attached that reconciles to the $10.6B market cap per NUVL press release). NUVL Year 1 - 10 = FY2027 - FY2036 analyst consensus per Seeking Alpha. The peer transactions take year 1 - 10 per the acquiree management. We will update this analysis when NUVL files their 14D9 with the SEC in about 4 weeks The attached analysis (that has not been verified) suggests NUVL is being acquired at one of the highest revenue multiples in this peer group (assuming analyst consensus is more or less accurate. Investors in $RVMD & $CELC may want to review. This is not investment advice $CLDX
1 · Reply
Bobear12
Bobear12 May. 23 at 9:38 PM
$ACLX Galectin Therapeutics (NASDAQ: GALT) is presenting new clinical analyses of its Phase 2b NAVIGATE trial for its lead drug, belapectin, at the EASL Congress. The presentations at the European Association for the Study of the Liver focus on preventing esophageal varices and improving liver biomarkers in patients with MASH cirrhosis.
0 · Reply
TeresaTrades
TeresaTrades Apr. 28 at 1:21 PM
Largest CALL OI decreases $PLTR $NOK $ACLX $LVS $IVZ
0 · Reply
TwongStocks
TwongStocks Apr. 24 at 6:21 PM
$ACLX Equity Corporate Actions Alert #2026 - 272 Information Regarding the Merger of Arcellx, Inc. (ACLX) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-272 The tender offer by Gilead Sciences, Inc. $GILD to acquire all of the outstanding common stock of Arcellx, Inc. $ACLX is scheduled to expire at 5:00 p.m. ET, on April 27, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on April 28, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 27, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 28th) and will be suspended effective April 29, 2026. The details are as follows:
0 · Reply
Mergerbrief
Mergerbrief Apr. 24 at 12:07 PM
$ACLX / $GILD – Tender Offer Expires Today
0 · Reply
TwongStocks
TwongStocks Apr. 17 at 12:32 PM
$GILD Gilead Receives All Required Regulatory Approvals for the Acquisition of $ACLX Arcellx and Extends Tender Offer https://www.businesswire.com/news/home/20260417916113/en/Gilead-Receives-All-Required-Regulatory-Approvals-for-the-Acquisition-of-Arcellx-and-Extends-Tender-Offer "The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions. "
0 · Reply
DonCorleone77
DonCorleone77 Apr. 1 at 8:16 PM
$ACLX $GILD Gilead extends tender offer to acquire Arcellx Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
0 · Reply
SBroomy
SBroomy Mar. 19 at 2:06 PM
$ACLX $SPY Unfazed by whatever is going on in the market
0 · Reply
Innovatenow
Innovatenow Mar. 7 at 5:11 AM
$ACLX https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-is-investigating-the-mergeraclx-vre-ehab-and-ceco-302704159.html
0 · Reply
Mergerbrief
Mergerbrief Mar. 6 at 12:38 PM
$ACLX / $GILD – Tender Offer File By date
0 · Reply
SBroomy
SBroomy Mar. 5 at 6:36 PM
$ACLX $SPY Arcellx have hold up very well since it's gains.
0 · Reply
Achandler787
Achandler787 Mar. 5 at 3:56 AM
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 27 at 2:20 AM
$ACLX congrats longs! $GILD should buy $ALT or $IMRX next 🚀
0 · Reply
IN0V8
IN0V8 Feb. 25 at 6:46 PM
$ACLX 2/24 Citigroup cuts to neutral from buy Citigroup raises target price to $115 from from $110 Leerink Partners cuts to market perform rating Leerink Partners raises target price to $115 from $109 Stifel cuts to hold from buy; cuts target price to $115 from $127 Truist Securities cuts to hold from buy; cuts PT to $120 from $134 UBS cuts to neutral from buy UBS raises target price to $115 from $100 Wells Fargo cuts to equal weight from overweight Wells Fargo raises target price to $115 from $100
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 7:17 PM
$GILD to acquire $ACLX for $115 per share in cash plus a $5 CVR, totaling $7.8B — strengthening its position in cell therapy 🚀 Gilead's strategic acquisition aims to streamline control over anito-cel therapy, enhancing its cell therapy position via Kite Pharma. ACLX shares soared 77.43% on the news. Discover the full implications here 👉 https://www.zacks.com/stock/news/2874572/gild-to-acquire-aclx-for-78b-gain-full-control-of-anito-cel?cid=sm-stocktwits-2-2874572-body-34988&ADID=SYND_STOCKTWITS_TWEET_2_2874572_BODY_34988
0 · Reply
IN0V8
IN0V8 Feb. 24 at 4:06 PM
$ACLX 2/23 Baird raises target price to $115 from $106 Piper Sandler cuts to neutral from overweight
0 · Reply